Oncolytic virotherapy: basic principles, recent advances and future directions.

Lin D, Shen Y, Liang T. · 2023

Read Oncolytic virotherapy: basic principles, recent advances and future directions. by Lin D, Shen Y, Liang T. (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc10090134.txt.

Introduction

Lin, Shen, and Liang review oncolytic virotherapy in a 2023 paper, from basic principles to future directions. Oncolytic viruses are viruses chosen or engineered to infect and burst cancer cells. Their attack can also wake up the immune system against the tumor, giving a double effect.

The review explains how these viruses are built and made safer and stronger. It surveys trials across cancer types and the results so far. It also covers pairing virus therapy with immune drugs. The paper gives readers a full tour of a therapy moving from idea to clinic.

Catalog record

CREATORLin D, Shen Y, Liang T.
YEAR2023
COLLECTIONPAPERS
FORMATTXT
FILE SIZE191 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC10090134

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Oncolytic virotherapy: basic principles, recent advances and future directions By Danni Lin, Yinan Shen, Tingbo Liang Published in: Signal Transduction and Targeted Therapy DOI: 10.1038/s41392-023-01407-6 ABSTRACT Abstract Oncolytic viruses (OVs) have attracted growing awareness in the twenty-first century, as they are generally considered to have direct oncolysis and cancer immune effects. With the progress in genetic engineering technology, OVs have been adopted as versatile platforms for developing novel antitumor strategies, used alone or in combination with other therapies. Recent studies have yielded eye-catching results that delineate the promising clinical outcomes that OVs would bring about in the future. In this review, we summarized the basic principles of OVs in terms of their classifications, as well as the recent advances in OV-modification strategies based on their characteristics, biofunctions, and cancer hallmarks. Candidate OVs are expected to be designed as “qualified soldiers” first by improving target fidelity and safety, and then equipped with “cold weapons” for a proper cytocidal effect, “hot weapons” capable of activating cancer immunotherapy, or “auxiliary weapons” by harnessing tactics such as anti-angiogenesis, reversed metabolic reprogramming and decomposing extracellular matrix around tumors. Combinations with other cancer therapeutic agents have also been elaborated to show encouraging antitumor effects. Robust results from clinical trials using OV as a treatment congruously suggested its significance in future application directions and challenges in developing OVs as novel weapons for tactical decisions in cancer treatment. Subject terms: Cancer therapy, Drug development INTRODUCTION Viruses used to be associated with the evil devil. However, oncolytic viruses (OVs) are comparable to be noble angels, as they can save lives. Oncolytic virotherapy is an emerging novel tumor therapeutic approach that selectively replicates in and destroys tumor cells while leaving normal cells undamaged.1,2 Initially, in the twentieth century, investigations carried out on the oncolytic effects were generally based on wild-type or naturally occurring viruses such as West Nile virus, rabies virus, yellow fever, hepatitis, etc.,3 and the mechanism was simply thought to be their intrinsic lytic characteristics. Approaching the year 2000, it is technically feasible to carry out an array of modifications on wild-type viruses by means of genetic engineering. Modified OVs can be armed with desired exogenous genes that could exert profound antitumor effects via different mechanisms. At first, the main focus of reconstructions was to improve target specificity, selective replication and oncolysis. Soon later, an elicited antigen-specific antitumor immunoreactive response during tumor lysis was appreciated, which is another advantage of OVs as immunotherapy.2 Strategies have, therefore, begun to shift toward developing viral vectors for enhancing immune responses within the tumors, or for adjusting tumor neovascularization, tumor metabolism and other aspects to counteract the malicious tumor microenvironment (TME) in recent years. This process can be graphically described as “soldiers” equipped with a variety of “sophisticated weapons” to cope with different situations. Also, it is equally important to arm a soldier with the right weapons to maximize tumor damage. The outcomes of OVs are determined by a three-way race among virus replication, immune activation and tumor growth.4 Unlike the theories of conventional chemoradiotherapy, OVs precisely lyse cancer cells by interacting with specific cellular receptors, or taking advantage of tumor-suppressor gene defects, downregulation of the antiviral pathway in tumor cells, or by designing virus vector with specific gene knockout. The benefits regarding different forms of cell death are various due to the characteristics of virus vectors and tumor cell type, and most of them can trigger immunogenic cell death (ICD), releasing tumor-associated antigens and initiating antitumor immune responses. However, it cannot be ignored that antiviral immunity can be triggered at the same time as the infection has been launched. Therefore, the selection and design of virus vectors are diversified and flexible, considering the balance among the viruses, TME and host immunity. Regarding the activation of tumor immunity, OVs seem to outperform the ICIs and other targeted drugs since ICIs specifically target the immune checkpoint, while small molecule drugs only target a certain molecule. In the context of OVs, a broader range of antitumor immunity activities would be aroused to fight against tumors. For example, the release of TAAs during oncolysis, the initiation of immunity, the promoted immune cell infiltration, improved recognition and killing abilities of immune cells, the reversal of the immunosuppressive microenvironment, and others (a detailed comparison of this part is presented in Bommareddy’s review).5 Compared with the limited effect of other treatment methods, OVs can carry out multiple “weapons” to kill tumors systematically and comprehensively in multiple ways. OVs can also help to regulate the abnormalities in TME, such as neovascularization, tumor metabolisms, and the stiff extracellular matrix barrier brought by tumor stromal cells. In short, oncolytic therapy offers various advantages. To date, scientists have made a number of preclinical attempts and clinical trials of both naturally occurring OVs (e.g., reovirus and vesicular stomatitis virus)6–8 and genetically engineered OVs (e.g., adenovirus, vaccinia virus and herpesvirus),9–11 with some encouraging data. From H101 for nasopharyngeal carcinoma admitted by China in 2005 to Delytact for malignant glioma approved in Japan in 2021,12,13 a total of four functionally compensatory OV products have been approved for clinical treatment. OV has gradually managed to secure its place as a powerful anticancer agent in cancer treatment options. As most investigators have found that OVs are ideally suitable for combination strategies compared to single modality therapies because of the complexity of mechanisms involved in the progress of OV to take action in the complex environment of tumors. The development of combination methods implementing antitumor drugs yields synergistic or additional antitumor benefits, for which clinical validations through well-designed and statistically sound clinical trials are required.14,15 This review provides a comprehensive overview of oncolytic virotherapy, especially addressing the basic principles of how OVs take effect in the context of complex TME. Furthermore, recent advances in genetic engineering strategies to construct versatile OVs will be discussed in full range. The accurately selected combination options for cancer treatment and the outcomes of ongoing associated clinical trials are especially worthwhile keeping an eye on because the valuable information would provide future directions for the development of more advanced OVs with maximized capabilities. THE DOMINATE TYPES OF OVS Regarding the antitumor mechanisms, although OVs share properties, different types or subtypes of viruses are being scrutinized for efficacies to cope with various pathological conditions. OVs are derived from single- or double-stranded DNA or RNA viruses according to nucleic acid type. ssRNA and dsDNA viruses are the most prevalent in OVs products, except for reovirus (dsRNA) and parvovirus (ssDNA). dsDNA viruses mainly include adenovirus, vaccinia virus, herpesvirus, etc., while ssRNA viruses are composed of two main categories: positive-sense (coxsackievirus, Seneca Valley virus, poliovirus) and negative-sense (measles virus, Newcastle Disease virus, vesicular stomatitis virus). The genetic information of positive-sense ssRNA viruses is directly translated into protein by ribosomes of host cells, while the nucleic acid of negative-sense ssRNA viruses is complementary to the viral mRNA, which must be transcribed into positive-sense RNA before it can be translated into protein. OVs can also be divided into naturally attenuated viral strains and genetically modified viral vectors according to their structures (Table 1). [Table: Features of selected oncolytic viruses] Herpesvirus Herpes simplex virus (HSV), an enveloped virus with dsDNA protected by the nucleocapsid, and surrounded by the tegument, has

Read the complete text